2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Transplantation, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Natural Language Processing, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Thromboembolism, Bone Marrow Failure Syndromes, Genetic Disorders, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, MDS, MPN, CML, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2834 Response matters: Improved leukemia-specific quality of life among older adults with AML who achieve treatment response

Sara M. Tinsley-Vance, PhD, APRN, AOCN, Ram Thapa, PhD2, Steven K. Sutton, PhD3, Cecile A Lengacher, RN, PhD, FAAN, FAPOS4, Areej R El-Jawahri, MD5, Martine Extermann, MD, PhD6, Rami Komrokji, MD7, Eric Padron, MD8, David Sallman, MD9, Andrew T Kuykendall, MD10, Onyee Chan, MD11, Alison Walker, MD12, Matthew Hewes, APRN13, Kristan Kersey, PA-C14, Michelle Tophkhane, DNP, APRN, FNP15, Kathryn Herricks, APRN16, Heather Buffington, DNP17, Dorothie Durosier Mertilus, PhD,APRN18, Jeffrey Lancet, MD19
1 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
2 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
3 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
4 University of South Florida, Tampa, Florida, United States
5 Massachusetts General Hospital, Boston, Massachusetts, United States
6 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
7 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
8 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
9 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
10 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
11 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
12 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
13 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
14 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
15 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
16 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
17 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
18 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
19 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Background: Older adults with AML often prioritize quality of life (QOL) and symptom control when making treatment decisions. However, limited evidence exists regarding whether achieving a treatment response, including complete remission (CR), complete remission with incomplete hematologic recovery (CRi), morphologic leukemia free state (MLFS), or partial remission (PR), is associated with improved patient-reported QOL and symptoms, and whether these benefits differ between intensive and non-intensive treatment approaches. We therefore examined the association between treatment response and patient-reported QOL and symptom burden among older adults receiving intensive or non-intensive therapy for AML.

Methods: This exploratory, hypothesis-generating analysis utilized prospectively collected data from the NIH-funded study, Development of a Quality-of-Life Decision-Making Model for Older Adults with Acute Myeloid Leukemia, a prospective cohort study designed to characterize patient-reported QOL and decision-making experiences among older adults undergoing treatment for AML. Baseline clinical, disease-related, frailty assessment, and patient-reported outcome (PRO) data were collected before initiation of therapy, intensive compared to non-intensive. Longitudinal PRO measures included the Brief Fatigue Inventory (BFI), Memorial Symptom Assessment Scale-Short Form (MSAS-SF), and Functional Assessment of Cancer Therapy-Leukemia version (FACT-Leu Total). These were completed by patients within 7 days of starting treatment and at days 30, 60, 90, and 180. At each assessment time point patients were classified as responders (CR, CRi, MLFS, or PR) or non-responders (no response). 

 A generalized estimating equations (GEE) model (a population-average interpretation, that handles the within-subject correlation across time points and is robust to the missingness) was fitted for each QOL measure. No significant response status and treatment interaction was detected; thus, we fitted a reduced GEE model for each measure pooling across both arms, with time point and treatment arm included as covariates.

Results: Among 171 older adults with newly diagnosed AML, 82 received intensive therapy and 89 received non-intensive therapy. Mean age was 70.6±6.5 years; patients receiving non-intensive therapy were older than those receiving intensive therapy (74.0 vs. 67.0 years; p<0.001). Baseline sociodemographic characteristics were otherwise similar between groups. ELN 2017 risk category differed by treatment intensity (p=0.002), with favorable-risk disease more common among patients receiving intensive therapy (22.0% vs. 4.5%) and adverse-risk disease more common among those receiving non-intensive therapy (69.7% vs. 52.4%). Frailty also differed between groups (p=0.028), with frailty more prevalent in the non-intensive cohort (36.0% vs. 18.3%) and fit/robust status more prevalent in the intensive cohort (63.4% vs. 44.9%).

Longitudinally, responders generally demonstrated lower fatigue and symptom burden and better leukemia-specific QOL than non-responders across treatment groups. In adjusted GEE models controlling for treatment arm and time point, responders had significantly higher FACT-Leu Total scores than non-responders (β=7.2, 95% CI 3.0-11.0; p<0.001). Responders also had lower BFI and MSAS-GDI scores, although these differences were not statistically significant (BFI: β=-4.6, 95% CI -13.0 to 3.4; p=0.256; MSAS-GDI: β=-2.2, 95% CI -4.7 to 0.32; p=0.088). No significant response-by-treatment interaction was observed for any PRO measure.

Conclusion: Among older adults with AML, achievement of a treatment response was associated with significantly better leukemia-specific QOL, measured with the FACT-Leu, independent of treatment intensity and assessment time point. Trends toward lower fatigue and symptom burden were also observed among responders, although these associations did not reach statistical significance. No evidence was found that the relationship between response status and PROs differed by treatment intensity. These findings are exploratory and should be interpreted cautiously given the limited number of non-responders and the potential for survivorship bias at later assessment time points.

Sara M. Tinsley-Vance, PhD, APRN, AOCN: No relevant conflicts of interest to declare.